C. Walkom

The first two cantharidin analogues displaying PP1 selectivity.

D. Young, M. Bowyer, A. McCluskey, 2002, Bioorganic & medicinal chemistry letters.

Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.

A. McCluskey, A. Chamberlin, J. Sakoff, 2004, Bioorganic & medicinal chemistry letters.

Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.

Adam McCluskey, S. Ackland, M. Bowyer, 2003, Bioorganic chemistry.

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

S. Ackland, A. McCluskey, J. Sakoff, 2001, Anti-cancer drug design.

Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.

S. Ackland, M. Bowyer, A. McCluskey, 2001, Bioorganic & medicinal chemistry letters.